Literature DB >> 11854771

Cannabinoids and the immune system.

T W Klein1, C A Newton, H Friedman.   

Abstract

The effect of cannabimimetic agents on the function of immune cells such as T and B lymphocytes, natural killer cells and macrophages has been extensively studied over the past several decades using human and animal paradigms involving whole animal models as well as tissue culture systems. From this work, it can be concluded that these drugs have subtle yet complex effects on immune cell function and that some of the drug activity is mediated by cannabinoid receptors expressed on the various immune cell subtypes. However, the overall role of the cannabinoid system of receptors and ligands in human health and disease is still unclear and requires extensive elucidation. Further studies will define the precise structure and function of the putative immunocannabinoid system, the potential therapeutic usefulness of these drugs in chronic diseases such as acquired immune deficiency syndrome and multiple sclerosis, the effects of these agents on tumour growth and induction of apoptosis, and the potential anti-inflammatory and proinflammatory properties of cannabimimetic compounds. It is likely that the cannabinoid system, along with other neuroimmune systems, has a subtle but significant role in the regulation of immunity and that this role can eventually be exploited in the management of human disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11854771     DOI: 10.1155/2001/326867

Source DB:  PubMed          Journal:  Pain Res Manag        ISSN: 1203-6765            Impact factor:   3.037


  19 in total

1.  Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

Authors:  Grzegorz Godlewski; Barbara Malinowska; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

Review 2.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

3.  Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model.

Authors:  Ming Zhang; Billy R Martin; Martin W Adler; Raj K Razdan; Jack I Jallo; Ronald F Tuma
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-24       Impact factor: 6.200

Review 4.  Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.

Authors:  Mary-Ann Fitzcharles; Winfried Häuser
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

5.  Synthesis of S-2-((S)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-(methyl-d3 )butanamide-d5 , octadeuterated JD5037.

Authors:  Malliga R Iyer; Resat Cinar; Nathan J Coffey; Robert J Chorvat; George Kunos
Journal:  J Labelled Comp Radiopharm       Date:  2017-08-02       Impact factor: 1.921

6.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

7.  Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study.

Authors:  Lidia Ruiz-Llorente; Silvia Ortega-Gutiérrez; Alma Viso; María G Sánchez; Ana M Sánchez; Carlos Fernández; José A Ramos; Cecilia Hillard; Miguel A Lasunción; María L López-Rodríguez; Inés Díaz-Laviada
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

8.  Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

9.  Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury.

Authors:  M Zhang; B R Martin; M W Adler; R K Razdan; D Ganea; R F Tuma
Journal:  Neuroscience       Date:  2008-01-25       Impact factor: 3.590

10.  CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury.

Authors:  Ming Zhang; Martin W Adler; Mary E Abood; Doina Ganea; Jack Jallo; Ronald F Tuma
Journal:  Microvasc Res       Date:  2009-03-28       Impact factor: 3.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.